Scholarlink

<p>Standardized angiographic endpoints for evaluating treatment success after thrombectomy in acute limb ischemia (ALI) are lacking, limiting comparability across trials and clinical practice. We developed the Thrombectomy in Limb Ischemia (TILI) score, a novel angiographic classification system to systematically assess the technical efficacy of thrombectomy in ALI of embolic origin. The TILI Score was designed through consensus by a Swiss-wide research group of specialists in angiology, vascular surgery, and interventional radiology. It comprises of two components: (1) <i>lesion recanalisation</i> (Grades 0–3), and (2) <i>peripheral embolisation</i> (Grades a–c, ±p), the latter assessed only if recanalisation is Grade 2 or 3. For the pilot validation, inter-reader reproducibility, 10 expert readers were asked to grade 10 representative post-thrombectomy angiograms after standardized training. Agreement was quantify using percentage agreement, Gwet’s agreement coefficient (AC2; quadratic and ordinal weights), and intra-class correlation coefficients (ICC). Nine readers completed the assessment. For the full composite scale agreement reached 93.6% (95% CI: 91.2–96.1), with substantial agreement reliability (Gwet’s AC2 = 0.74 and 0.72) and ICC of 0.756 (95% CI: 0.449–0.886). For the main recanalisation grade (0–3), agreement was higher: 95.1% (95% CI: 92.1–98.2), with almost perfect agreement reliability (AC2 of 0.875 and 0.862). The TILI Score is the first structured and reproducible tool to classify the technical success of thrombectomy in ALI in patients without preexisting occlusive disease. It demonstrated substantial to almost perfect interobserver agreement among experts and may serve as a standardized endpoint for future thrombectomy trials. Broader clinical validation is necessary to define outcome-relevant thresholds.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The thrombectomy in limb ischemia score (TILI-Score): score proposal and results of an interobserver readability survey

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月18日

查看全文
  • Aleksandra Tuleja,
  • Stephanie Zbinden,
  • Ludovica Ettorre,
  • Maria-Antonela Ruffino,
  • Greicy Heymann,
  • Céline Deslarzes,
  • Tim Sebastian,
  • Anna-Leonie Menges,
  • Sarah Maike Bernhard,
  • Fabrice Noël Helfenstein,
  • Michel Bosiers,
  • Marc Schindewolf

摘要

Standardized angiographic endpoints for evaluating treatment success after thrombectomy in acute limb ischemia (ALI) are lacking, limiting comparability across trials and clinical practice. We developed the Thrombectomy in Limb Ischemia (TILI) score, a novel angiographic classification system to systematically assess the technical efficacy of thrombectomy in ALI of embolic origin. The TILI Score was designed through consensus by a Swiss-wide research group of specialists in angiology, vascular surgery, and interventional radiology. It comprises of two components: (1) lesion recanalisation (Grades 0–3), and (2) peripheral embolisation (Grades a–c, ±p), the latter assessed only if recanalisation is Grade 2 or 3. For the pilot validation, inter-reader reproducibility, 10 expert readers were asked to grade 10 representative post-thrombectomy angiograms after standardized training. Agreement was quantify using percentage agreement, Gwet’s agreement coefficient (AC2; quadratic and ordinal weights), and intra-class correlation coefficients (ICC). Nine readers completed the assessment. For the full composite scale agreement reached 93.6% (95% CI: 91.2–96.1), with substantial agreement reliability (Gwet’s AC2 = 0.74 and 0.72) and ICC of 0.756 (95% CI: 0.449–0.886). For the main recanalisation grade (0–3), agreement was higher: 95.1% (95% CI: 92.1–98.2), with almost perfect agreement reliability (AC2 of 0.875 and 0.862). The TILI Score is the first structured and reproducible tool to classify the technical success of thrombectomy in ALI in patients without preexisting occlusive disease. It demonstrated substantial to almost perfect interobserver agreement among experts and may serve as a standardized endpoint for future thrombectomy trials. Broader clinical validation is necessary to define outcome-relevant thresholds.